The present invention relates to: a recombinant adenovirus comprising a promoter, a ribozyme targeting human telomerase reverse transcriptase (hTERT) mRNA, and a p53 gene, in an adenovirus backbone with deletions of E1 and E3; a host cell into which the recombinant adenovirus is introduced; and a pharmaceutical composition comprising the the recombinant adenovirus as an active ingredient for preventing or treating cancers. It was confirmed that the recombinant adenovirus of the present invention was used to inhibit the activity of hTERT mRNA, which is specifically overexpressed in cancer cells, by cutting the hTERT mRNA through a trans-splicing ribozyme, and simultaneously to allow p53, which is a therapeutic gene, to be expressed, thereby effectively killing cancer cells. Particularly, it was confirmed that the liver tissue-specific migration, particularly selective motility toward cancer cells, was improved. Thus, the recombinant adenovirus of the present invention can be used as a gene therapeutic agent against hepatoma cancer or metastatic liver cancer, which does not show cytotoxicity to normal cells regardless of systemic administration thereof and which has improved selective motility. [Reference numerals] (AA) CMV promoter; (BB) Therapeutic gene; (CC) h TERT ribozyme; (DD) Ad frame (E1&E3); (EE) Ribozyme (+)
展开▼
